GlassScriptPhysician profile
Frances Leung
NPI 1861579641
$6,000.72
in general payments reported to CMS, 2019-2025
25 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $681 · 2020: $253 · 2021: $688 · 2022: $1,064 · 2023: $990 · 2024: $1,035 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,314.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $845.64 | 2022-2025 | Miebo, Vyzulta, Alden Scleral Zenlens |
| Coopervision INC. | $837.88 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Onefit Contact Lens |
| Alcon Vision LLC | $724.32 | 2019-2025 | Precision7, Clareon, Rocklatan |
| Biotissue Holdings INC. | $711.98 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $582.60 | 2019-2025 | Acuvue |
| Oyster Point Pharma, INC. | $415.64 | 2022-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $261.68 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $249.50 | 2021-2023 | |
| Allergan, INC. | $185.22 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $162.71 | 2022-2024 | Acthar |
| Abbvie INC. | $150.13 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $137.35 | 2024-2025 | Xdemvy |
| Rxsight INC | $111.74 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $102.56 | 2019-2021 | |
| Harrow Eye, LLC | $96.97 | 2025 | Vevye |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abb Con-Cise Optical Group LLC | $72.96 | 2019-2021 | |
| Sight Sciences, INC. | $65.11 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $60.29 | 2019-2021 | |
| Genentech USA, INC. | $54.11 | 2019 | |
| Horizon Therapeutics Plc | $51.91 | 2022-2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $39.15 | 2021 | |
| Topcon Healthcare, INC. | $25.11 | 2024 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Dompe US, INC. | $19.03 | 2024 | Oxervate |
| Glaukos Corporation | $17.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Leung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.